Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
House committee advances task force to study emerging mental‑health therapies after broad testimony
Loading...
Summary
The House Committee on Health advanced SB 3199 to create a task force to study emerging therapies — including psychedelic‑assisted treatments — and assigned the John A. Burns School of Medicine to lead the effort after wide testimony from veterans, clinicians and advocates.
The House Committee on Health on March 20 voted to advance Senate Bill 3199, creating a task force to study emerging mental‑health therapies and prepare the state for clinical, training and regulatory challenges should the federal government reschedule certain agents.
Committee action and agency assignment: The chair proposed and the committee adopted amendments making the John A. Burns School of Medicine (JABSOM) at the University of Hawai‘i the responsible entity to host the task force and designating the JABSOM appointee as task‑force chair. The committee also adopted technical amendments recommended by the Department of Law Enforcement to give the Narcotics Enforcement Division authority to handle state rescheduling actions and shortened an administrative timeline from 90 to 30 days as offered in the hearing record.
Why it matters: Testimony centered on the potential of psychedelic‑assisted therapies to help people with PTSD, treatment‑resistant depression and other severe conditions, and on the state’s need to prepare training, regulation and clinical infrastructure. Veterans, clinicians and advocacy groups described access barriers that currently force some patients to seek care outside the U.S.
What supporters said: Dozens of witnesses urged the state to move quickly to study and prepare for emerging therapies. Logan Davidson of Veterans Exploring Treatment Solutions described veterans’ experiences obtaining care abroad and recommended statutory changes to ensure safe, supervised access in state settings. Vicky Farmer and other veterans and family members gave emotional testimony describing life‑changing clinical results they attributed to these therapies. Dr. John Clifton, director of research and education for VETS, urged the committee to act quickly so Hawaii can implement task‑force recommendations once the FDA and federal authorities move.
Caveats and agency concerns: The Department of the Attorney General flagged an undefined “entity” in the bill language that could create uncertainty about administrative responsibility; DOH noted federal law currently prohibits some pharmacologic agents and recommended prudence. Some state officials suggested placing the task force in an academic or research institution rather than DOH because of DOH’s limited experience managing clinical trials.
Next steps: With JABSOM designated to lead the group and the Narcotics Enforcement Division assigned rescheduling authority, the task force will produce recommendations for how the state should organize clinical access, workforce training, safety rules and any regulatory changes required once federal law changes or new FDA‑approved therapies emerge.
